Press Releases

Gilead Sciences to Release Fourth Quarter and Year End 2007 Financial Results on Wednesday, January 23, 2008

Conference Call and Webcast to Follow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 16, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its fourth quarter and year end 2007 financial results will be released on Wednesday, January 23, 2008, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead will webcast a conference call live on the company's internet site. The call will be led by John Milligan, PhD, Chief Operating Officer; Caroline Dorsa, Senior Vice President and Chief Financial Officer and Kevin Young, Executive Vice President, Commercial Operations. Gilead management will discuss the company's fourth quarter and year end 2007 results, provide an overview of the company, and an outlook and financial guidance for 2008.

To access the webcast via the internet, log on to Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-866-713-8567 (U.S.) or 1-617-597-5326 (international) and dial the participant passcode 70709078 to access the call. Telephone replay is available approximately two hours after the call through 4:00 p.m. Eastern Time, January 26, 2008. To access, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 21873491. The webcast will be archived on for one year.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715
Investor Relations

SOURCE: Gilead Sciences, Inc.